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Abstract
Background: Anti TNF drugs have been widely used in rheumatoid arthritis (RA) but only 70 to 80 % of patients
respond to this therapy. Exploring the mode of action of anti-TNF drugs remains important in order to improve the
efficiency of the treatment and enhance our knowledge of inflammation. TNF-α exists as classical soluble cytokine as
well as transmembrane protein (tmTNF-α). Evidence suggests that tmTNF-α can induce reverse signaling. In the present
study, we have explored consequences of reverse signaling in human monocytes using certolizumab pegol (CZP).
Methods: Monocytes were purified from healthy blood donors and were incubated with CZP. Nuclear translocation of
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) was evaluated by wide-field microscopy and cell fractionation. Heme
oxygenase 1 (HO-1) was assessed by RT-qPCR and western blot. Monocytes were stimulated with lipopolysaccharide
(LPS). IL-1β was quantitated by RT-qPCR. Reactive oxygen species (ROS) were evaluated by flow cytometry using the
H2DCFDA fluorescent marker.
Results: CZP induced rapid minimal ROS production and Nrf2 nuclear translocation. This was followed by HO-1 mRNA
and protein production. IL-1β induction by LPS was inhibited at the mRNA and protein level. At a later time-point, CZP
was able to counteract the strong production of ROS induced by LPS.
Reverse signaling was suggested by short kinetics of Nrf2 translocation, extensive washing of CZP and the use of
anti-TNF-Rs antibodies.
Conclusion: Our data suggest a novel mechanism of ROS modulation by CZP. This observation sheds new light on the
function of reverse signaling and on potential mechanisms of action of anti-TNF drugs.
Keywords: Transmembrane TNF-α, Reverse signaling, Anti-TNF, Monocytes, Nrf2, Reactive oxygen species,
Inflammation, Rheumatoid arthritis
Background
Anti-TNF drugs have been widely used in rheumatoid
arthritis (RA) for more than 15 years [1]. Only 70–80 %
of patients respond to this therapy. To date, there is no
explanation for this lack of efficacy [2]. Further under-
standing of the mode of action of anti-TNF drugs is
much needed to improve the efficacy of the treatment
and enhance our knowledge of inflammation.
The rationale for anti-TNF therapy in RA is the in-
hibition of the cytokine cascade, such as IL1, IL6 and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [1]. In addition to neutralizing soluble TNF-α, anti-
TNF may also induce signal reverse via transmembrane
TNF- α (tm TNF-α) [3]. TNF-α, and most of the other
members of the TNF superfamily are also transmembrane
proteins. Evidence suggests that the membrane-integrated
ligands can receive signals and act as receptors, which can
transmit feedback signals, called reverse signaling, into the
cell [4, 5]. A previous study showed that pre-treatment of
monocytes with anti-TNF induces the resistance of mono-
cytes to lipopolysaccharide (LPS) [6]. In monocytes from
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patients with RA, anti-TNF stimulation was shown to
decrease the secretion of inflammatory cytokine and
to induce apoptosis [7]. These observations were at-
tributed to reverse signaling. The role of reverse sig-
naling in the initiation and perpetuation of arthritis is
not established.
Monocytes are attractive targets for the treatment of RA
[8]. Our laboratory is interested in the characterization of
the role of tm-TNF-α in monocytes as a possible cell tar-
get of anti-TNF, which is now commonly used in the treat-
ment of RA. In a previous study, we investigated the role
of TNF-α and adalimumab on CD36 expression in human
monocytes. F(ab’)2 fragment obtained from adalimumab
induced an increase in CD36 expression due to reverse
signaling depending on reactive oxygen species (ROS) [9].
As nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is in-
duced upon ROS production [10–14] and is involved in
CD36 induction [15, 16], we hypothesized that it could be
induced by anti-TNF. Nrf2 is a redox-sensitive basic leu-
cine zipper transcription factor involved in the transcrip-
tional regulation of many antioxidant and cell protective
genes. It plays a role in the control of inflammation. For
example, genetic disruption of Nrf2 in different mouse
models increases the mortality of mice in response to sep-
tic shock, increases the severity of arthritis, and leads to
severe allergen-driven airway inflammation and hyper-
responsiveness [17, 18].
HO-1 is an enzyme regulated by Nrf2 [19]. In inflamma-
tion, heme oxygenase 1 (HO-1) protects cells from oxida-
tive damage during stress [20]. In a model of genetic
inactivation of HO-1, mice are vulnerable to mortality and
hepatic necrosis when challenged with endotoxin [21]. In
a human case of HO-1 deficiency the patient presented
with growth retardation, anemia, iron deposition, and vul-
nerability to stressful injury [22]. Endothelial cells from
mice with HO-1 knockout (KO) have enhanced sensitivity
to complement [23]. Anti-inflammatory effects of HO-1
usually result from the degradation of pro-inflammatory
free heme, and the production of the anti-inflammatory
compounds as carbon monoxide (CO), biliverdin/bilirubin
and free iron [24]. HO-1 could thus be a therapeutic
target in RA.
In this work we thus used certolizumab pegol (CZP)
to investigate the induction of Nrf2 through tmTNF-α.
CZP was chosen because it is a monovalent Fab anti-
TNF antibody linked with a polyethylene glycol (PEG)
fragment that has no Fc fragment [7, 25]. We showed
that CZP induced rapid ROS induction and nuclear
translocation of Nrf2 and expression of HO-1. Moreover,
LPS-induced ROS expression and IL-1 production were
attenuated by CZP, suggesting an effect on toll-like re-
ceptor (TLR)4-induced inflammation. Our data point to




LPS from Eschericia coli 055:B5 was purchased from
Sigma (St Louis, MO, USA). Nrf2 (H300) antibodies
were purchased from Santa Cruz Biotechnology (Dallas,
TX, USA), anti-rabbit IgG horse radish peroxidase
(HRP)-linked antibodies, Alexa Fluor 488 F(ab’)2 anti-
rabbit IgG, tatabox binding protein (TBP) and HO-1
(P249) antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (ABS16) antibodies
were purchased from Millipore (Temecula, CA, USA).
Blocking antibodies against TNF receptor 1 (TNFR1)
(clone #16805) and TNFR2 (clone #22210) were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Anti-CD14 (HCD14) antibody was from Biolegend, San
Diego, CA, USA. H2DCFDA (C-2938) was purchased
from Life Technologies (Carlsbad, CA, USA). The 4',6-
diamidino-2-phenylindole (DAPI) was purchased from
Biolegend (San Diego, CA, USA). The diphenyleneiodo-
nium chloride (DPI) and wortmannin inhibitors were
purchased from Sigma.
Preparation of peripheral blood mononuclear cells
(PBMC) and monocyte purification
PBMC were isolated from healthy blood donors (Etablis-
sement Français du Sang Transfusion Center, Toulouse,
France). Ethical approval was obtained from the Transfu-
sion Center. Informed consent was obtained from blood
donors. PBMC were separated by ficoll density gradient
centrifugation at 700 g for 20 minutes. They were then re-
suspended in PBS 2 mM ethylenediaminetetraacetic acid
(EDTA) and thoroughly washed (centrifugation at 350 g
for 8 minutes six times). The percentage of monocytes
was evaluated by flow cytometry on a FACSCalibur cyt-
ometer (BD Bioscience, San Diego, CA, USA) with an
anti-CD14 (HCD14) antibody (Biolegend, San Diego, CA,
USA)). CD14+ monocytes were purified by negative
immunomagnetic bead separation using Dynabeads
Untouched Human Monocytes kit (Life Technologies,
Carlsbad, CA, USA). Purity of CD14+ monocytes
was >90 %. Monocytes were then incubated in Macro-
phage SFM medium (Life Technologies) and plated one
hour before applying any treatment. Cells were incubated
with CZP (5 μg/ml) for the indicated times, then thor-
oughly washed as described [6, 25].
Quantitative real-time PCR
Total RNA from 4 × 106 monocytes was isolated using
High Pure RNA Isolation Kit (Roche Diagnostics GmbH,
Mannheim, Germany) and complementary DNA (cDNA)
synthesized with RevertAid Minus Reverse Transcriptase
(Thermo Fisher Scientific, Waltham, MA, USA). Gene
expression was performed using LightCycler 480 SYBR
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Green Master Mix and LightCycler 480 System instrument
(Roche Diagnostics GmbH). All primers were designed
using ProbeFinder Software (Roche Applied Science
website), and synthetized by Sigma Life Science (St Quentin
Fallavier, France) (Table 1).
ROS measurements
For intracellular ROS measurement, we used the
H2DCFDA compound. Monocytes (4 × 10
5 cells) were
grown in a 24 well-plate in 0.5 ml Macrophage SFM
medium. All treatment conditions were performed in
duplicate. Monocytes were incubated, or not, for 5, 15
and 30 minutes with 5 μg/ml of CZP. Then, culture
medium was discarded and replaced by PBS containing
2 μM H2DCFDA. Monocytes were incubated for 30 mi-
nutes and then detached from the well in 300 μl of PBS
5 mM EDTA at 4 °C. The level of fluorescence (geomet-
ric mean) was measured by flow cytometry on a FACS-
Calibur cytometer.
In another experiment, monocytes were incubated, or
not, for 1 h with 5 μg/ml of CZP, washed three times
with medium to remove unfixed CZP, and then incu-
bated for 18 h in medium containing LPS. The ROS pro-
duction was then measured. All cytometry data were
analyzed by FlowJo (TreeStar Inc, Ashland, OR, USA).
Western blot analysis
Total extracts from 4 × 106 monocytes lysed in 50 μl of
Laemmli buffer were denatured at 95 °C for 10 minutes
and sonicated: 15–20 μl were run on Novex NuPAGE
4–12 % Bis-Tris mini gels and transferred on nitrocellulose
membrane with X-Cell blot module (Life Technologies).
After incubation with primary and secondary HRP-
coupled antibodies, labeled proteins were visualized
by enhanced chemiluminescence with ECL Prime
Western Blotting Detection Reagent (GE Healthcare,
Piscataway, NJ, USA) on a ChemiDoc XRS+ imaging
system (Bio-Rad Laboratories, Hercules, CA, USA).
All images were analyzed with the Image Lab 5.0
software (Bio-Rad). Antibodies to GAPDH and TBP
were used to normalize the loading quantities of pro-
tein in the different lanes of the gels.
Preparation of nuclear extracts
Monocytes (4–5 × 106) grown in 6-well plates and 2 ml
of Macrophage SFM medium were scraped in 1 ml of
ice-cold PBS supplemented by protease inhibitor cocktail
(PIC, P8340, Sigma) at 1:100 dilution and harvested at
800 g and 4 °C for 4 minutes. Cells were resuspended in
50 μl of lysis buffer (10 mM TRIS pH 7.3, 1 mM MgCl2,
250 mM sucrose, 0.25 % NP40, 1:50 PIC) and left on ice
for 10 minutes. After centrifugation at 1500 g for 4 mi-
nutes at 4 °C, the nuclear enriched pellet was lysed in
50 μl of Laemmli buffer. The lysates were denatured for
8 minutes at 95 °C and sonicated before western blot
analysis.
Immunofluorescence microscopy
Monocytes (3 × 105 cells) in 0.5 ml of Macrophage SFM
medium were plated for 1 h on a glass coverslip in a 24-
well plate and incubated, or not, by 5 μg/ml CZP. After
30 minutes, the medium was removed by aspiration and
cells were fixed and permeabilized with 250 μl methanol
at 80 % over 4 minutes at –20 °C. After washing with
PBS and PBS 0.25 % BSA, cells were incubated with the
Nrf2 (H300) antibody at 1:250 dilution for 1 h. Cells
were rinsed three times with PBS-BSA and then incu-
bated with secondary anti-rabbit AF488 antibody for an-
other 1 h. DAPI at a final concentration of 0.3 μM was
added for 10 minutes and cells were washed another
three times with PBS-BSA. The coverslip glass was
mounted on a microscopic slide with Mowiol mounting
medium. All observations were made on an Apotome
Zeiss device equipped with a × 63 objective. Images were
obtained using Zen software (Carl Zeiss Microscopy
GmbH, Jena, Germany).
Statistics
All experiments were performed more than three times.
The values are expressed as the mean ± standard devi-
ation (SD). The t test was used to assess the significance
of differences between two conditions. All p values are
two-sided, and p values equal to or below 0.05 were con-
sidered significant.
Results
Anti-TNF induces ROS production and nuclear
translocation of Nrf2 translocation in human monocytes
In a previous report, we observed that the increase in
CD36 expression induced by the anti-TNF agent adali-
mumab was dependent on nicotinamide adenine di-
nucleotide phosphate-oxidase (NADPH) activation [9].
We showed that CZP induces cytoplasmic ROS produc-
tion shortly after incubation (within 5–30 minutes) with
monocytes (Fig. 1a). As Nrf2 is involved in the response
to ROS and is involved in the regulation of CD36 ex-
pression [16], we assessed its nuclear translocation in
monocytes. As shown in Fig. 1b, the anti-TNF CZP in-
duced the nuclear translocation of Nrf2. Nuclear trans-
location was also confirmed by western blot of cellular
Table 1 Primers sequences used for qPCR
Gene Accession
number
Forward primer Reverse primer
gapdh J04038.1 cagcctcaagatcatcagca gtcttctgggtggcagtgat
hmox1 NM_002133.2 ggcagagggtgatagaagagg agctcctgcaactcctcaaa
IL1B NM_000576.2 aaagcttggtgatgtctggtc ggacatggagaacaccacttg
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and nuclear extracts (Fig. 1c). Expression of Nrf2 in the
nucleus increased rapidly after incubation with anti-TNF
(Fig. 1d).
Anti-TNF induces HO-1
To further illustrate the functionality of the targeting of
Nrf2 by anti-TNF we assessed the messenger RNA
(mRNA) production of HO-1, a key enzyme implicated
in heme degradation and regulated by Nrf2 [19]. As
shown in Fig. 2a, CZP induced a twofold increase of
HO-1 mRNA after 4 h of cell culture. A similar increase
in HO-1 protein was also observed after 6 and 16 h of
cell culture (Fig. 2b-d).
Induction of HO-1 by anti-TNF is dependent upon ROS
production and PI3 kinase activity
Nicotinamide adenine dinucleotide phosphate-oxidase
[NADPH] is a major source of ROS [26] which, as a
source of stress, are involved in the activation of Nrf2
[11–13]. To test if NADPH was implicated in HO-1 in-
duced by anti-TNF, we used an inhibitor of ROS produc-
tion induced by NADPH, DPI. Figure 3a and b show
that DPI used alone induced ROS on its own, as already
described [27]. However, DPI consistently inhibited the
induction of HO-1 observed with CZP, indicating a role
for NADPH in the induction of HO-1. PI3k is activated
by calcium flux and has been reported to activate
NADPH oxydase [28]. As shown in Fig. 3a and b,
wortmannin, a PI3K inhibitor, completely blocked the
induction of HO-1 observed with anti-TNF CZP. This
suggests that PI3K is involved in the induction of HO-1
by CZP.
Induction of HO-1 is not due to TNFR and results from
reverse signaling
Induction of HO-1 may result from blocking the inter-
action of TNF-α with its receptors. To elucidate whether
the induction of HO-1 by anti-TNF results from a re-
verse signaling phenomenon we inhibited the TNFR1
and TNFR2 by specific blocking antibodies. As shown in
Fig. 4, the anti-TNF-induced increase in HO-1 expres-
sion was still observed in the presence of the anti-
TNFR1 and TNFR2 blocking antibody. This suggests
that the induction of HO-1 by CZP was not mediated by
TNFR and thus, resulted from reverse signaling.
CZP inhibits LPS-induced IL-1β and ROS production
Previous studies have shown that anti-TNF decreases
the sensitivity of TLR signaling in monocytes [6, 29].
The mechanism has not been reported in detail. As HO-
1 and Nrf2 are reported to be involved in the regulation
of TLR4 signaling [30, 31], we investigated the impact of
anti-TNF on TLR-4-induced ROS production. In a first
step, we validated the repression of LPS-induced IL1β by
anti-TNF. After short incubation of monocytes with
CZP, cells were extensively washed and analyzed. As
Fig. 1 Certolizumab pegol (CZP) induces rapid production of reactive oxygen species (ROS) and nuclear translocation of nuclear factor (erythroid-
derived 2)-like (Nrf2). Monocytes were incubated, or not, with CZP (5 μg/ml) and ROS production was assessed by H2DCFCA using flow
cytometry. The time course of rapid ROS production over 30 minutes is shown in monocytes from four different healthy donors (a). Monocytes
were incubated, or not, with CZP (5 μg/ml) for 90 minutes, and cellular localization of Nrf2 was analyzed by wide-field microscopy using an anti-Nrf2
antibody. 4',6-diamidino-2-phenylindole (DAPI) was used as control for nucleus staining (b). Cytoplasmic and nuclear extracts were prepared after
90 minutes of cell culture and analyzed for Nrf2 detection (c). Time course analysis of Nrf2 translocation in nuclear fraction-enriched cell extracts of
monocytes incubated, or not, with CZP (5 µg/ml) (d). TATA box binding protein (TBP) was used as control (d). Data are representative of four experi-
ments (b, c, d). MFI geometric mean of fluorescence intensity
Boyer et al. Arthritis Research & Therapy  (2016) 18:56 Page 4 of 9
shown in Fig. 5, CZP induced a decrease in LPS-induced
IL1β production at the mRNA (Fig. 5a) and protein
(Fig. 5b), levels. This suggested that CZP modulated the
TLR4-mediated inflammatory signal. We then evaluated
the modulation of LPS-induced ROS by CZP. We ob-
served (Fig. 5c) that pre-treatment of monocytes with
CZP, significantly inhibited the ROS production in-
duced by TLR4 stimulation with LPS. A representa-
tive cytometry experiment is shown in Fig. 5d. This
suggests that engaging tmTNF-α modified the mono-
cyte response to LPS.
Discussion
In this work, we showed that anti-TNF CZP induced rapid
ROS production and subsequent nuclear translocation of
Nrf2 in human monocytes. As a consequence, HO-1 ex-
pression was increased. Moreover, LPS-induced IL1ß and
ROS production were inhibited by CZP. To our know-
ledge, this is the first description of Nrf2 activation and
ROS modulation by anti-TNF via reverse signaling.
Reverse signaling has been characterized on the basis
of several factors. First, induction of HO-1 was still ob-
served in the presence of specific anti-TNF receptors 1
Fig. 2 Certolizumab pegol (CZP) induces heme oxygenase 1 (HO-1) expression. Monocytes were incubated, or not, with CZP (5 μg/ml) for 4 h of
culture. RNA was isolated and qRT-PCR was performed to quantify HO-1 mRNA. Quantification of five experiments. *Paired t test <0.05 (a).
Monocytes were incubated, or not, with CZP (5 μg/ml) during 6 or 16 h of culture. HO-1 protein was assessed by western blot (b). Quantification
of five experiments was performed at 6h (c) and at 16h (d). Paired t test <0.05. GAPDH glyceraldehyde 3-phosphate dehydrogenase
Fig. 3 Roles of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) and Pi3 kinase in the induction of heme oxygenase 1 (HO-1) by
certolizumab pegol (CZP). Monocytes were incubated, or not, with CZP 5 μg/ml in the presence or not of diphenyleneiodonium chloride (DPI)
(10 μM) and wortmannin (0.4 μM) over 16 h. HO-1 was assessed by western blot. One representative blot is shown (a). Quantification of three
western blot experiments was performed. *Paired t test <0.05 (b). GAPDH glyceraldehyde 3-phosphate dehydrogenase, WM Wortmannin
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Fig. 4 Heme oxygenase 1 (HO-1) induction by anti-TNF certolizumab pegol (CZP) is due to reverse signaling. Monocytes were incubated, or not,
with CZP (5 μg/ml) for 16 h in the presence of TNF receptor 1 (TNFR1) and TNFR2 (5 μg/ml) blocking antibody. HO-1 protein expression was
assessed by western blot (a). Quantification of four western blot experiments was performed. Paired t test p = 0.05 (b). GAPDH glyceraldehyde
3-phosphate dehydrogenase, Abs antibodies
Fig. 5 Certolizumab pegol (CZP) directly induces inhibition of the toll-like receptor 4 pathway. Expression of IL1β: monocytes were incubated, or
not, with CZP (5 μg/ml) for 1 h, washed, then stimulated with lipopolysaccharide (LPS) (10 ng/ml) for 16 h. IL1β mRNA was assessed by qRT-PCR.
Results are expressed as relative level of IL1β mRNA mean ± SD in three experiments (a). IL1β protein was assessed by western blot in monocytes
stimulated as in (a) for 16 h (b). Data shown are representative of three experiments. Monocytes were incubated, or not, with CZP (5 μg/ml) for
1 h, washed and stimulated with LPS (10 ng/ml) for 16 h. The level of ROS production was expressed as the percentage of variation of the geo-
metric mean fluorescence intensity (MFI) of H2DFCDA as analyzed by flow cytometry (c) in five experiments. *Paired t test <0.05 for comparison
of LPS and LPS + CZP. A representative cytometry experiment in shown (d). GAPDH glyceraldehyde 3-phosphate dehydrogenase
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and 2 blocking antibodies and thus, did not result from
TNF-α neutralization by CZP. Second, TNF-α itself is
known to induce Nrf2 [32]. If our results were due to
mere neutralization of soluble TNF, results opposite to
ours would have rather been observed on HO-1 and
Nrf2. Third, the kinetics of the induction of ROS were
rapid and inhibition of TLR signaling after washing away
the anti-TNF was still observed. A more direct approach
would probably be to test monocytes with knocked
down TNFR1/2 and with expression of non-cleavable
TNF. However, we observed that these cells express high
levels of Nrf2 when transfected with small interfering
RNA (siRNA) or infected with viruses (our unpublished
data), making this approach difficult.
The mechanism leading to Nrf2 activation is likely to
be due to the relatively small amount of induced ROS as
early as 5 minutes after stimulation with anti-TNF (10–
50 % increase). Our data suggest that reverse signaling
in monocytes is an immediate or early event that con-
trols subsequent monocyte activation. LPS stimulation
induced a much stronger increase (400 %) in ROS that
was potently reduced by CZP in a 16-h timeframe.
Moreover, CZP, like adalimumab [9], induced CD36 ex-
pression (see Additional file 1). Altogether, the induction
of CD36, the resistance to LPS and the rapid induction
of Nrf2 by anti-TNF may represent features of macro-
phage polarization to an anti-inflammatory activation
phenotype. As a comparison, IL4 has been shown to de-
liver a signal that counteracts LPS-induced polarization
and induces CD36 [33, 34]. Future experiments will
determinethe consequences of reverse signaling induced
by anti-TNF on monocyte polarization.
Besides playing a role in the removal of ROS-induced
electrophiles and protection of cells from injuries, Nrf2
play a role in the control of inflammation [35]. In a
mouse model of colitis, inflammation was increased in
the colonic tissues of Nrf2-/- mice compared with their
wild-type Nrf2+/+ counterparts [36]. Nrf2 is activated in
the joints of arthritic mice and of patients with RA [18].
Data exploring the existence of a link between response
to anti-TNF and induction of Nrf2 in RA are needed.
Induction of HO-1 in arthritis has been the topic of a
large number of publications. A study reported that
infliximab, an anti-TNF agent, increased HO-1 expres-
sion in human monocytes from patients with RA [37].
The authors suggest that it resulted from the inhibition
of the downregulation of HO-1 by TNF-α. However, the
persistence of HO-1 induction with anti-TNF-R blocking
antibodies observed in our study suggests an active
mechanism of anti-TNF in HO-1 induction [32]. At the
cellular level, HO-1 decreases the secretion of metallo-
proteases by chondrocytes [38]. It has also been shown
to inhibit phospholipase A2 induced by TNF-α in syn-
ovial fibroblasts in RA [39] and has been reported to
favor protection of the endothelial cells to complement
injury [23]. Thus, HO-1 may be related to the resolution
of inflammation and arthritis.
An important result of this work appears to be the
inhibition of the TLR pathway reverse signaling in-
duced by anti-TNF. Such inhibition has previously
been reported, but no clear mechanism was proposed
[5]. Our present data on the decreased IL-1β produc-
tion by CZP confirm those published by Nesbitt et al.
and further show that inhibition occurs at the level of
specific mRNA production [25]. A recent publication
reported that IL-6 is also inhibited in mouse macro-
phages [40]. This needs to be explored in human
macrophages.
Conclusions
Figure 6 depicts our data and our current view of reverse
signaling induced by CZP. Our current study describes
antioxidant response induced by anti-TNF-induced re-
verse signaling in monocytes. Induction of Nrf2 and
HO-1, and decrease of LPS-induced ROS and IL-1β in
monocytes, may contribute to the therapeutic effects of
anti-TNF agents in inflammatory conditions.
Fig. 6 Schematic representation of certolizumab pegol (CZP) action on
transmembrane TNF (tmTNF) and subsequent regulation. The Anti-TNF
agent CZP induces rapid reactive oxygen species (ROS) production
through its binding to tmTNF-α. Nuclear factor (erythroid-derived
2)-like 2 (Nrf2) is translocated to the nucleus. Heme oxygenase 1
(HO-1) and CD36 are induced. The toll-like receptor 4 (TLR4) ligand
lipopolysaccharide (LPS), which mimics some of the triggers of rheuma-
toid arthritis (RA), induces strong production of ROS and IL-1β, which
are both inhibited by pretreatment with CZP
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Additional file
Additional file 1: Induction of CD36 by certolizumab pegol (CZP).
Human monocytes were incubated for 24 hours with 5 μg/ml CZP. CD36
expression was evaluated by flow cytometry using anti-CD36-PE antibody.
Summary of five independent experiments: p <0.01. MFI geometric mean of
fluorescence intensity. (TIF 97 kb)
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